Comparative Pharmacology
Head-to-head clinical analysis: AZULFIDINE versus DELZICOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZULFIDINE versus DELZICOL.
AZULFIDINE vs DELZICOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfasalazine is a prodrug that is cleaved by gut bacteria to form 5-aminosalicylic acid (5-ASA) and sulfapyridine. 5-ASA acts locally in the colon to reduce inflammation by inhibiting prostaglandin synthesis and leukotriene formation, antioxidant effects, and inhibition of cytokine production. Sulfapyridine provides additional immunosuppressive effects.
Delzicol is a prodrug of mesalamine (5-aminosalicylic acid). It is converted to mesalamine in the colon by bacterial azoreduction. Mesalamine reduces inflammation in the colon by inhibiting prostaglandin production via cyclooxygenase inhibition and decreasing leukotriene synthesis via lipoxygenase pathway. It also scavenges reactive oxygen species and inhibits cytokine production.
Oral, 500 mg to 1 g twice daily, initially 500 mg twice daily, increase to 1 g twice daily after 1 week if tolerated; maximum 3 g/day.
800 mg orally 3 times daily for ulcerative colitis; mesalamine 4 g retention enema once daily or 4 g foam once daily for proctosigmoiditis.
None Documented
None Documented
Sulfapyridine: 10-14 hours; 5-ASA: 0.6-1.4 hours (rapid acetylation). Clinical context: Twice-daily dosing maintains therapeutic sulfapyridine levels.
The terminal elimination half-life of mesalamine is approximately 0.5-1.5 hours after oral administration. For the acetylated metabolite, it is 5-10 hours. The short half-life necessitates multiple daily dosing for sustained colonic anti-inflammatory effect.
Renal: 75% (sulfapyridine metabolites), 15% (5-aminosalicylic acid). Biliary/fecal: 10%.
Approximately 40-50% of the absorbed dose is excreted renally as mesalamine (5-ASA) and its acetylated metabolite (N-Ac-5-ASA). Fecal excretion accounts for the remainder, including unabsorbed drug and biliary elimination.
Category C
Category C
Aminosalicylate
Aminosalicylate